Delivery Order SPE2DB25D2204-SPE2DB25FTGLK
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Esbriet (pirfenidone) 267 mg tablets in a quantity of 270 units, valued at $3,425.95. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for completion by September 17, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency issued a delivery order on June 16, 2025, to AmerisourceBergen Drug Corp for the supply of Esbriet (pirfenidone) 267 mg tablets in a quantity of 270 tablets, with a ceiling value of $3,425.95. This order is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 9, 2025....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Esbriet (pirfenidone) 267 mg tablets in a quantity of 270 tablets. This is a firm fixed price delivery order with a ceiling value of $3,425.95 and an ultimate completion date of August 18, 2025. The contract is not set-aside and represents a competitive award to the vendor, with performance to take place at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for Esbriet 801 mg tablets (90-count supply) on July 7, 2025, with an ultimate completion date of July 28, 2025. This is a competitively awarded, firm fixed-price contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for the supply of Esbriet 267 mg tablets (270 count) on July 31, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Esbriet (pirfenidone) is a pharmaceutical treatment for idiopathic pulmonary...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,425.95 for Esbriet (pirfenidone) 801 mg tablets, a quantity of 90 units, with an ultimate completion date of September 25, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Esbriet 801 mg tablets (90-count package) with a ceiling value of $3,425.95. This is a firm fixed price delivery order with an ultimate completion date of August 4, 2025, and carries no set-aside designation, indicating it was competitively awarded. The performance location is AmerisourceBergen's facility in Conshohocken, Pennsylvania, which serves as the company's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Esbriet 267 mg tablets (270 count) under a firm fixed-price contract valued at $20,555.70, with an ultimate completion date of October 17, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of AmerisourceBergen's substantial role as a critical pharmaceutical distributor within the federal medical supply chain. The order will be...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Esbriet (pirfenidone) 267 mg tablets in a quantity of 270 units. This non-set-aside, competitively awarded contract carries a firm fixed price structure with an ultimate completion date of October 8, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $3,425.95 to AmerisourceBergen Drug Corp for the supply of Esbriet (pirfenidone) 801 mg tablets in a quantity of 90 units. This non-competitive, firm fixed-price delivery order is scheduled for completion by September 17, 2025, with performance at AmerisourceBergen's corporate office facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement under the company's existing contract vehicle with...
- SPE2DB25D2204Indefinite Delivery Contract
- SPE2DB25D2204-SPE2DB25FTGLKDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 8, 2025, for the supply of Esbriet (pirfenidone) 801 mg tablets in a 90-count package. This is a competitively awarded, firm fixed-price delivery order with a ceiling value of $3,425.95 and an ultimate completion date of May 30, 2025. The contract carries no set-aside designation, indicating open competition among qualified vendors. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime indefinite delivery vehicle enables the contractor to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including the Defense Health Agency and U.S. Coast Guard. The company's substantial contract portfolio with DLA demonstrates its capability to fulfill federal pharmaceutical procurement requirements across multiple therapeutic domains through competitive awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 5/8/25 |